Acquisition of Injectable Triptorelin Cytostatic Medication of 22.5 Mg for Oncological Patients Chuquisaqueño Institute of Oncology Corresponding to the First Quarter
Acquisition of Injectable Monoclonal Medication Pertuzumab 420 Mg for Oncological Patients Instituto Chuquisaqueño de Oncologia Corresponding to the First Quarter